Business Context and Reporting Period
This Form 8-K is filed by BioZone Pharmaceuticals, Inc. (not Cocrystal Pharma, Inc.) for the reporting period of August 15, 2011. The registrant is a Nevada corporation headquartered in Englewood Cliffs, NJ. The filing addresses a triggering event involving the Company's wholly owned subsidiaries, BioZone Laboratories, Inc. and Equalan, LLC.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, or margin data. The primary financial disclosure relates to debt obligations:
- Outstanding Debt: $2,043,033 (aggregate principal and interest) on four promissory notes.
- Collateral: Notes are secured by a first priority lien on all assets of the subsidiaries.
- Guarantees: Full repayment is personally guaranteed by the Company's President/Chief Scientific Officer and Executive Vice President.
Material Changes
The Company acquired all stock of BioZone Labs and Equalan, which triggered a change of ownership exceeding 25%. This acquisition constituted an event of default under the terms of the promissory notes held by a financial institution. Consequently, the Lender declared the entire unpaid principal and accrued interest immediately due and payable as of August 15, 2011.
Outlook, Risks, and Contingencies
The immediate risk is the acceleration of debt repayment totaling over $2 million. The filing identifies a material contingency regarding the Company's ability to satisfy this immediate financial obligation. No forward-looking guidance or management commentary regarding future operations or liquidity plans is provided in this specific report.
Investor Verification Checklist
- Verify the Company's current cash position and ability to repay the $2,043,033 accelerated debt.
- Confirm the status of negotiations with the Lender regarding the default and potential restructuring.
- Assess the impact of the first priority lien on subsidiary assets on future financing capabilities.
- Review the personal financial standing of the executive guarantors.